Ventyx Biosciences (NASDAQ:VTYX) Insider Sells $97,851.00 in Stock

Ventyx Biosciences, Inc. (NASDAQ:VTYX) insider John Nuss sold 12,675 shares of the business’s stock in a transaction dated Thursday, December 18th. The stock was sold at an average price of $7.72, for a total transaction of $97,851.00. Following the completion of the sale, the insider directly owned 489,481 shares of the company’s stock, valued at $3,778,793.32. The trade was a 2.52% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink.

Ventyx Biosciences Trading Up 12.9%

Shares of NASDAQ VTYX opened at $8.74 on Monday. The company has a market capitalization of $623.69 million, a price-to-earnings ratio of -5.83 and a beta of 1.22. Ventyx Biosciences, Inc. has a twelve month low of $0.78 and a twelve month high of $10.55. The business has a 50 day simple moving average of $7.90 and a 200-day simple moving average of $4.52.

Ventyx Biosciences (NASDAQ:VTYX) last posted its quarterly earnings results on Thursday, November 6th. The company reported ($0.32) EPS for the quarter, beating the consensus estimate of ($0.45) by $0.13. As a group, equities analysts predict that Ventyx Biosciences, Inc. will post -2.09 earnings per share for the current year.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in the stock. Hudson Bay Capital Management LP acquired a new stake in Ventyx Biosciences in the second quarter worth approximately $34,000. Pallas Capital Advisors LLC acquired a new position in shares of Ventyx Biosciences during the 2nd quarter valued at $38,000. Engineers Gate Manager LP bought a new stake in shares of Ventyx Biosciences in the 2nd quarter worth $42,000. Persistent Asset Partners Ltd acquired a new stake in shares of Ventyx Biosciences in the third quarter valued at $51,000. Finally, Jump Financial LLC acquired a new stake in shares of Ventyx Biosciences in the second quarter valued at $53,000. Institutional investors and hedge funds own 97.88% of the company’s stock.

Wall Street Analysts Forecast Growth

Several analysts recently issued reports on VTYX shares. Oppenheimer raised their price target on Ventyx Biosciences from $9.00 to $14.00 and gave the stock an “outperform” rating in a report on Monday, October 27th. HC Wainwright upgraded Ventyx Biosciences from a “neutral” rating to a “buy” rating and set a $18.00 target price on the stock in a research note on Wednesday, November 5th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Ventyx Biosciences in a report on Wednesday, October 8th. Canaccord Genuity Group boosted their price objective on Ventyx Biosciences from $14.00 to $16.00 and gave the stock a “buy” rating in a research report on Friday, November 7th. Finally, Wells Fargo & Company lifted their target price on Ventyx Biosciences from $11.00 to $14.00 and gave the company an “overweight” rating in a research note on Friday, November 7th. Four investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $15.50.

Ventyx Biosciences Company Profile

Ventyx Biosciences, Inc, a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. The company’s lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn’s disease. It is also developing VTX002, a sphingosine 1 phosphate receptor modulator that is in Phase II clinical trials for the treatment of ulcerative colitis; and VTX2735, a peripheral-targeted NOD-like receptor protein 3 inflammasome inhibitor to treat patients with cryopyrin-associated periodic syndrome.